시장보고서
상품코드
1150067

세계 골관절염 시장-시장 점유율, 규모, 동향, 산업 분석 : 치료 유형별, 질환 유형별, 유통 채널별, 투여 경로별, 지역별, 부문 예측(2022-2030년)

Osteoarthritis Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Drugs, Assistive Devices); By Disease Type; By Distribution Channel; By Route of Administration; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 116 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 골관절염 시장 규모는 2030년까지 153억 달러에 이를 것으로 예측됩니다.

세계 골관절염(Osteoarthritis) 시장을 조사했으며, 시장 개요/시장 규모 및 예측/동향/촉진 요인·억제 요인/치료 유형별·질환 유형별·유통 채널별·투여 경로별·지역별 분석/기업 개요 등 정보를 제공합니다.

목차

제1장 소개

  • 리포트 설명
    • 조사의 목적
    • 시장 범위
    • 전제 조건
  • 이해관계자

제2장 주요 요약

  • 시장의 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보원
    • 1차 정보
    • 2차 정보

제4장 세계의 골관절염 시장 통찰

  • 골관절염-산업 스냅샷
  • 골관절염 시장 역학
    • 촉진 요인과 기회
    • 억제 요인과 과제
  • Porter’s Five Forces
    • 공급기업의 협상력
    • 신규 참가자의 위협
    • 구매자의 협상력
    • 대체품의 위협
    • 기존 기업 간의 경쟁력
  • PESTLE 분석
  • 골관절염 산업의 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 골관절염 시장 : 치료 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 골관절염 시장, 치료 유형별(2018-2030년)
  • 약제
    • 세계의 골관절염 시장, 약제별, 지역별(2018-2030년)
    • 관절내 보충제
    • 비스테로이드성 항염증제
    • 진통제
    • 코르티코스테로이드
  • 보조 장치
    • 세계의 골관절염 시장, 보조 장치별, 지역별(2018-2030년)

제6장 세계의 골관절염 시장 : 유통 채널별

  • 주요 조사 결과
  • 소개
    • 세계의 골관절염 시장, 유통 채널별(2018-2030년)
  • 병원 약국
    • 세계의 골관절염 시장, 병원 약국별, 지역별(2018-2030년)
  • 소매 약국
    • 세계의 골관절염 시장, 소매 약국별, 지역별(2018-2030년)
  • 약국
    • 세계의 골관절염 시장, 약국별, 지역별(2018-2030년)
  • 전자상거래
    • 세계의 골관절염 시장, 전자상거래별, 지역별(2018-2030년)

제7장 세계의 골관절염 시장 : 질환 유형별

  • 주요 조사 결과
  • 소개
    • 세계의 골관절염 시장, 질환 유형별(2018-2030년)
  • 무릎 골관절염
    • 세계의 골관절염 시장, 무릎 골관절염별, 지역별(2018-2030년)
  • 척추 골관절염
    • 세계의 골관절염 시장, 척추 골관절염별, 지역별(2018-2030년)
  • 발·발목 골관절염
    • 세계의 골관절염 시장, 발·발목 골관절염별, 지역별(2018-2030년)
  • 어깨 골관절염
    • 세계의 골관절염 시장, 어깨 골관절염별, 지역별(2018-2030년)
  • 손 골관절염
    • 세계의 골관절염 시장, 손 골관절염별, 지역별(2018-2030년)

제8장 세계의 골관절염 시장 : 투여 경로별

  • 주요 조사 결과
  • 소개
    • 세계의 골관절염 시장, 투여 경로별(2018-2030년)
  • 비경구 경로
    • 세계의 골관절염 시장, 비경구 경로별, 지역별(2018-2030년)
  • 국소 경로
    • 세계의 골관절염 시장, 국소 경로별, 지역별(2018-2030년)
  • 경구 경로
    • 세계의 골관절염 시장, 경구 경로별, 지역별(2018-2030년)

제9장 세계의 골관절염 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • 골관절염 시장의 평가, 지역별(2018-2030년)
  • 골관절염 시장-북미
    • 북미 : 골관절염 시장, 치료 유형별(2018-2030년)
    • 북미 : 골관절염 시장, 투여 경로별(2018-2030년)
    • 북미 : 골관절염 시장, 유통 채널별(2018-2030년)
    • 북미 : 골관절염 시장, 질환 유형별(2018-2030년)
    • 골관절염 시장-미국
    • 골관절염 시장-캐나다
  • 골관절염 시장-유럽
    • 유럽 : 골관절염 시장, 치료 유형별(2018-2030년)
    • 유럽 : 골관절염 시장, 투여 경로별(2018-2030년)
    • 유럽 : 골관절염 시장, 유통 채널별(2018-2030년)
    • 유럽 : 골관절염 시장, 질환 유형별(2018-2030년)
    • 골관절염 시장-영국
    • 골관절염 시장-프랑스
    • 골관절염 시장-독일
    • 골관절염 시장-이탈리아
    • 골관절염 시장-스페인
    • 골관절염 시장-네덜란드
    • 골관절염 시장-러시아
  • 골관절염 시장-아시아 태평양
    • 아시아 태평양 : 골관절염 시장, 치료 유형별(2018-2030년)
    • 아시아 태평양 : 골관절염 시장, 투여 경로별(2018-2030년)
    • 아시아 태평양 : 골관절염 시장, 유통 채널별(2018-2030년)
    • 아시아 태평양 : 골관절염 시장, 질환 유형별(2018-2030년)
    • 골관절염 시장-중국
    • 골관절염 시장-인도
    • 골관절염 시장-일본
    • 골관절염 시장-말레이시아
    • 골관절염 시장-인도네시아
    • 골관절염 시장-한국
  • 골관절염 시장-중동·아프리카
    • 중동·아프리카 : 골관절염 시장, 치료 유형별(2018-2030년)
    • 중동·아프리카 : 골관절염 시장, 투여 경로별(2018-2030년)
    • 중동·아프리카 : 골관절염 시장, 유통 채널별(2018-2030년)
    • 중동·아프리카 : 골관절염 시장, 질환 유형별(2018-2030년)
    • 골관절염 시장-사우디 아라비아
    • 골관절염 시장-남아프리카
    • 골관절염 시장-이스라엘
    • 골관절염 시장-아랍 에미리트 연방
  • 골관절염 시장-남미
    • 남미 : 골관절염 시장, 치료 유형별(2018-2030년)
    • 남미 : 골관절염 시장, 투여 경로별(2018-2030년)
    • 남미 : 골관절염 시장, 유통 채널별(2018-2030년)
    • 남미 : 골관절염 시장, 질환 유형별(2018-2030년)
    • 골관절염 시장-멕시코
    • 골관절염 시장-브라질
    • 골관절염 시장-아르헨티나

제10장 경쟁 상황

  • 확대·인수 분석
    • 확대
    • 인수
  • 파트너십/협업/협정/전시

제11장 기업 개요

  • ABIOGEN PHARMA SpA
  • Assertio Therapeutics, Inc
  • Abbott Laboratories Incorporation
  • Apotex Inc
  • Ampio Pharmaceuticals Inc
  • Bayer AG
  • Eli Lilly and Company
  • Horizon Therapeutics plc
  • Johnson & Johnson
  • Merck Sharp & Dohme Corp
  • Mylan NV
  • Novartis AG
  • Pfizer Inc
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • Tolmar Pharmaceuticals, Inc
  • Teva Pharmaceutical Industries Ltd
  • Zimmer Biomet Holding
LYJ 22.11.30

The global osteoarthritis market size is expected to reach USD 15.30 billion by 2030, according to a new study by Polaris Market Research. The report "Osteoarthritis Market Share, Size, Trends, Industry Analysis Report, By Treatment Type (Drugs, Assistive Devices); By Disease Type; By Distribution Channel; By Route of Administration; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising senior population and the rising prevalence of osteoarthritis are the main drivers of the market. For instance, as per the Centers for Disease Control and Prevention (CDC), 54.4 million US people, or one in four, have some type of arthritis, and by 2040, that number is expected to rise to 78 million.

Although there are more than 100 different kinds of arthritis, osteoarthritis (OA), which affects 32.5 million US adults, is the most widespread variety. 88% of those with OA are 45 years of age or older, and 43% are 65 years of age or older. There are significant societal and individual costs associated with the high frequency of arthritis.

Additionally, there have been technological developments, and improvements in diagnostics, are the factors boosting the market growth over the forecast period. Knee kinesiography, an advanced medical tool, is transforming how doctors treat osteoarthritis of the knee. As stated by the Public Health Agency of Canada, this type of osteoarthritis affects about four million Canadians or 13.6% of the community. When compared to males (11.1% and 7.5 per 1,000 persons per year), women(16.1% and 10.0 per 1,000 persons per year, respectively) have a greater frequency and prevalence of osteoarthritis diagnoses.

Further, in January 2022, TrialSpark announced the establishment of High Line Bio after acquiring from Merck KGaA the global license to sprifermin. Sprifermin is a technologically advanced disease-modifying recombinant version of human fibroblast development factor 18 that is being investigated as potential osteoarthritis (OA) treatment by encouraging cartilage formation.

One of the most unmet medical requirements among musculoskeletal disorders, OA is a degenerative joint disease that occurs partially due to cartilage loss. Thus, the rising prevalence of OA among the senior population and the development of technologically advanced treatments for OA are the factors boosting the market growth over the forecast period.

Additionally, the desire for minimally invasive surgical methods, greater public awareness, better treatment alternatives, and patient willingness to pursue therapy are all anticipated to support the expansion of the market.

Osteoarthritis Market Report Highlights

Knee osteoarthritis segment is anticipated to grow at a significant CAGR over the forecast period due to the high occurrence of knee osteoarthritis across the globe

Parental route segment accounted for the highest revenue share. This can be ascribed to the widespread use of the parenteral route for giving osteoarthritis treatments because of its simplicity, improved pharmacokinetics, and improved pharmacodynamics, which lead to higher patient compliance.

Asia Pacific is expected to grow at a fastest CAGR over the projected period on account of a rise in osteoarthritis incidence, a growth in the number of women, an expansion in health care spending, and a lack of physical activity

The global market includes Apotex Inc., Ampio Pharmaceuticals Inc., Bayer AG, Flexion Therapeutics, Inc., GlaxoSmithKline PLC, Horizon Therapeutics plc, Reckitt Benckiser Group PLC, Sanofi SA, Tolmar Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., and Zimmer Biomet Holding

Polaris Market Research has segmented the osteoarthritis market report based on treatment type, disease type, distribution channel, route of administration, and region:

Osteoarthritis, Treatment Type Outlook (Revenue - USD Billion, 2018 - 2030)

Drugs

Viscosupplementation Agents

Nonsteroidal Anti-inflammatory Drugs

Naproxen

Aspirin

Diclofenac

Ibuprofen

Other NSAIDs

Analgesics

Duloxetine

Acetaminophen

Corticosteroids

Assistive Devices

Osteoarthritis, Disease Type Outlook (Revenue - USD Billion, 2018 - 2030)

Knee Osteoarthritis

Spine Osteoarthritis

Foot & Ankle Osteoarthritis

Shoulder Osteoarthritis

Hand Osteoarthritis

Osteoarthritis, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Drug Stores

E-Commerce

Osteoarthritis, Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)

Parenteral Route

Topical Route

Oral Route

Osteoarthritis, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Osteoarthritis Market Insights

  • 4.1. Osteoarthritis - Industry Snapshot
  • 4.2. Osteoarthritis Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence of osteoarthritis
      • 4.2.1.2. Growing population susceptible to osteoarthritis
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Commercialization of alternatives
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Osteoarthritis Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Osteoarthritis Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
  • 5.3. Drugs
    • 5.3.1. Global Osteoarthritis Market, by Drugs, by Region, 2018 - 2030 (USD Billion)
    • 5.3.2. Viscosupplementation Agents
      • 5.3.2.1. Global Osteoarthritis Market, by Viscosupplementation Agents, by Region, 2018 - 2030 (USD Billion)
    • 5.3.3. Nonsteroidal Anti-inflammatory Drugs
      • 5.3.3.1. Global Osteoarthritis Market, by Nonsteroidal Anti-inflammatory Drugs, by Region, 2018 - 2030 (USD Billion)
      • 5.3.3.2. Naproxen
      • 5.3.3.2.1. Global Osteoarthritis Market, by Naproxen, by Region, 2018 - 2030 (USD Billion)
      • 5.3.3.3. Aspirin
      • 5.3.3.3.1. Global Osteoarthritis Market, by Aspirin, by Region, 2018 - 2030 (USD Billion)
      • 5.3.3.4. Diclofenac
      • 5.3.3.4.1. Global Osteoarthritis Market, by Diclofenac, by Region, 2018 - 2030 (USD Billion)
      • 5.3.3.5. Ibuprofen
      • 5.3.3.5.1. Global Osteoarthritis Market, by Ibuprofen, by Region, 2018 - 2030 (USD Billion)
      • 5.3.3.6. Other NSAIDs
      • 5.3.3.6.1. Global Osteoarthritis Market, by Other NSAIDs, by Region, 2018 - 2030 (USD Billion)
    • 5.3.4. Analgesics
      • 5.3.4.1. Global Osteoarthritis Market, by Analgesics, by Region, 2018 - 2030 (USD Billion)
      • 5.3.4.2. Duloxetine
      • 5.3.4.2.1. Global Osteoarthritis Market, by Duloxetine, by Region, 2018 - 2030 (USD Billion)
      • 5.3.4.3. Acetaminophen
      • 5.3.4.3.1. Global Osteoarthritis Market, by Acetaminophen, by Region, 2018 - 2030 (USD Billion)
    • 5.3.5. Corticosteroids
      • 5.3.5.1. Global Osteoarthritis Market, by Corticosteroids, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Assistive Devices
    • 5.4.1. Global Osteoarthritis Market, by Assistive Devices, by Region, 2018 - 2030 (USD Billion)

6. Global Osteoarthritis Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Osteoarthritis Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Osteoarthritis Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Drug Stores
    • 6.5.1. Global Osteoarthritis Market, by Drug Stores, by Region, 2018 - 2030 (USD Billion)
  • 6.6. E-Commerce
    • 6.6.1. Global Osteoarthritis Market, by E-Commerce, by Region, 2018 - 2030 (USD Billion)

7. Global Osteoarthritis Market, by Disease Type

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 7.3. Knee Osteoarthritis
    • 7.3.1. Global Osteoarthritis Market, by Knee Osteoarthritis, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Spine Osteoarthritis
    • 7.4.1. Global Osteoarthritis Market, by Spine Osteoarthritis, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Foot & Ankle Osteoarthritis
    • 7.5.1. Global Osteoarthritis Market, by Foot & Ankle Osteoarthritis, by Region, 2018 - 2030 (USD Billion)
  • 7.6. Shoulder Osteoarthritis
    • 7.6.1. Global Osteoarthritis Market, by Shoulder Osteoarthritis, by Region, 2018 - 2030 (USD Billion)
  • 7.7. Hand Osteoarthritis
    • 7.7.1. Global Osteoarthritis Market, by Hand Osteoarthritis, by Region, 2018 - 2030 (USD Billion)

8. Global Osteoarthritis Market, by Route of Administration

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 8.3. Parenteral Route
    • 8.3.1. Global Osteoarthritis Market, by Parenteral Route, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Topical Route
    • 8.4.1. Global Osteoarthritis Market, by Topical Route, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Oral Route
    • 8.5.1. Global Osteoarthritis Market, by Oral Route, by Region, 2018 - 2030 (USD Billion)

9. Global Osteoarthritis Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Osteoarthritis Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Osteoarthritis Market - North America
    • 9.3.1. North America: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.3.5. Osteoarthritis Market - U.S.
      • 9.3.5.1. U.S.: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.3.6. Osteoarthritis Market - Canada
      • 9.3.6.1. Canada: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 9.4. Osteoarthritis Market - Europe
    • 9.4.1. Europe: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.5. Osteoarthritis Market - UK
      • 9.4.5.1. UK: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.6. Osteoarthritis Market - France
      • 9.4.6.1. France: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.7. Osteoarthritis Market - Germany
      • 9.4.7.1. Germany: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.8. Osteoarthritis Market - Italy
      • 9.4.8.1. Italy: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.9. Osteoarthritis Market - Spain
      • 9.4.9.1. Spain: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.10. Osteoarthritis Market - Netherlands
      • 9.4.10.1. Netherlands: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.4.11. Osteoarthritis Market - Russia
      • 9.4.11.1. Russia: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 9.5. Osteoarthritis Market - Asia Pacific
    • 9.5.1. Asia Pacific: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.5.5. Osteoarthritis Market - China
      • 9.5.5.1. China: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.5.6. Osteoarthritis Market - India
      • 9.5.6.1. India: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.5.7. Osteoarthritis Market - Japan
      • 9.5.7.1. Japan: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.5.8. Osteoarthritis Market - Malaysia
      • 9.5.8.1. Malaysia: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.5.9. Osteoarthritis Market - Indonesia
      • 9.5.9.1. Indonesia: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.5.10. Osteoarthritis Market - South Korea
      • 9.5.10.1. South Korea: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 9.6. Osteoarthritis Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.6.5. Osteoarthritis Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.6.6. Osteoarthritis Market - South Africa
      • 9.6.6.1. South Africa: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.6.7. Osteoarthritis Market - Israel
      • 9.6.7.1. Israel: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.6.8. Osteoarthritis Market - UAE
      • 9.6.8.1. UAE: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
  • 9.7. Osteoarthritis Market - Latin America
    • 9.7.1. Latin America: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.7.5. Osteoarthritis Market - Mexico
      • 9.7.5.1. Mexico: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.7.6. Osteoarthritis Market - Brazil
      • 9.7.6.1. Brazil: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)
    • 9.7.7. Osteoarthritis Market - Argentina
      • 9.7.7.1. Argentina: Osteoarthritis Market, by Treatment Type, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Osteoarthritis Market, by Route of Administration, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Osteoarthritis Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Osteoarthritis Market, by Disease Type, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. ABIOGEN PHARMA S.p.A
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Assertio Therapeutics, Inc
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Abbott Laboratories Incorporation
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Apotex Inc
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Ampio Pharmaceuticals Inc
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Bayer AG
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Eli Lilly and Company
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Horizon Therapeutics plc
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Johnson & Johnson
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Merck Sharp & Dohme Corp
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Mylan N.V
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Novartis AG
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. Pfizer Inc
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Reckitt Benckiser Group PLC
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Sanofi SA
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Tolmar Pharmaceuticals, Inc
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Teva Pharmaceutical Industries Ltd
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Zimmer Biomet Holding
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제